Skip to main content
Article thumbnail
Location of Repository

Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group

By F Icli, H Akbulut, A Uner, B Yalcin, E Baltali, M Altinbas, Ş Coşkun, S Komurcu, M Erkisi, A Demirkazik, F C Senler, O Sencan, A Büyükcelik, C Boruban, H Onur, N Zengin and S D Sak


Our objective was to determine whether oral etoposide and cisplatin combination (EoP) is superior to paclitaxel in the treatment of advanced breast cancer (ABC) patients pretreated with anthracyclines. From December 1997 to August 2003, 201 patients were randomised, 100 to EoP and 101 to paclitaxel arms. Four patients in each arm were ineligible. The doses of etoposide and cisplatin were 50 mg p.o. twice a day for 7 days and 70 mg m−2 intravenously (i.v.) on day 1, respectively, and it was 175 mg m−2 on day 1 for paclitaxel. Both treatments were repeated every 3 weeks. A median of four cycles of study treatment was given in both arms. The response rate obtained in the EoP arm was significantly higher (36.3 vs 22.2%; P=0.038). Median response duration was longer for the EoP arm (7 vs 4 months) (P=0.132). Also, time to progression was significantly in favour of the EoP arm (5.5 vs 3.9 months; P=0.003). Median overall survival was again significantly longer in the EoP arm (14 vs 9.5 months; P=0.039). Toxicity profile of both groups was similar. Two patients in each arm were lost due to febrile neutropenia. The observed activity and acceptable toxicity of EoP endorses the employment of this combination in the treatment of ABC following anthracyclines

Topics: Clinical Studies
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1994). Clinical activity of chronic oral etoposide in previously treatment metastatic breast cancer.
    2. (1995). Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute referral center.
    3. (2002). Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/ advanced breast cancer pretreated with anthracyclines.
    4. (1998). sAC (adriamycin+cyclophosphamide)7two cycles of EP (etoposide+ cisplatin) in node positive patients with breast cancer. Ann Oncol 12: 1011–1013 Icli F, Demirkazik A

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.